Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06290141 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Name: A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — clinical trial record (NCT06290141)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: VITALIZE

StatusRecruiting

PhasePhase 3

SponsorSanofi

Started2024-08-21

View on ClinicalTrials.gov ↗

The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.

Amendment history 4 changes detected by DataLookout

2026-08-27

Trial sites expanded: 129 → 135 locations

2026-06-16

Trial sites expanded: 123 → 128 locations

2026-05-19

Trial sites expanded: 118 → 122 locations

2026-05-07

Trial sites expanded: 115 → 118 locations

Trial Details

NCT Number	NCT06290141
Lead Sponsor	Sanofi
Conditions	Chronic Inflammatory Demyelinating Polyneuropathy
Enrollment	160 participants
Start Date	2024-08-21
Primary Completion	2027-07-09 (estimated)
Study Completion	2029-01-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-26